Biomea Fusion, Inc. (BMEA) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 10.48M USD | Liabilities, Current |
| Cash and equivalents | 34.82M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $10.48M | $34.82M | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $9.29M | $44.69M | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $11.10M | $55.81M | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $15.56M | $46.64M | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $17.57M | $56.22M | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $19.82M | $35.86M | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $21.67M | $58.28M | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $27.57M | $87.95M | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $25.16M | $113.29M | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $25.25M | $144.92M | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $22.86M | $176.87M | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $16.21M | $199.09M | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $14.36M | $222.91M | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $18.77M | $86.30M | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $19.10M | $111.90M | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $12.59M | $132.31M | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $9.36M | $148.48M | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $7.96M | $156.22M | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $4.64M | $145.74M | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $5.64M | $156.97M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $4.94M | $166.04M | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $3.92M | $18.89M | (m) | $36.00K | (m) | (m) |
| 2020-12-31 | (m) | $1.62M | $61.70M | (m) | $16.00K | (m) | (m) |
| 2020-09-30 | (m) | (m) | $8.08M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | $9.20M | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | $37.00K | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | $239.00K | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B |